The impact of tumor resection on survival and functional outcomes for patients with primary central nervous system lymphoma

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY
{"title":"The impact of tumor resection on survival and functional outcomes for patients with primary central nervous system lymphoma","authors":"","doi":"10.1016/j.clineuro.2024.108551","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The role of tumor resection remains undetermined in treating primary central nervous system lymphomas (PCNSLs). This study aimed to clarify the impact of tumor resection on survival and functional outcomes, and to identify subgroups benefiting from resection.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed records from 2010 to 2021 for PCNSL diagnosed at Chang Gung Memorial Hospital, Linkou. Patients were categorized by extent of resection: gross total resection (GTR), partial resection (PR), and biopsy. Univariate and multivariate analyses were performed to identify prognostic factors for survival and functional outcomes. Subgroup analysis was conducted to characterize patients who benefit from tumor resection.</p></div><div><h3>Results</h3><p>Of 88 patients, 12 had GTR, 25 had PR, and 51 received biopsy. GTR correlated with longer progression free survival (PFS) (HR 0.25, <em>p</em>=0.039), remaining significant in multivariate analysis (adjusted HR 0.09, <em>p</em>=0.004). In solitary PCNSLs, GTR also independently predicted longer PFS (adjusted HR 0.13, <em>p</em>= 0.023). Patients with dominant tumors measuring ≥ 3 cm trended towards improved overall survival (OS) with cytoreductive surgery versus biopsy (median survival 38.6 months vs 22.3 months, <em>p</em>=0.083). Age ≥ 60 years (adjusted OR 16.9, <em>p</em> = 0.008) and preoperative Karnofsky Performance Scale ≤ 70 (adjusted OR 4.97, <em>p</em> = 0.049) predicted poorer functional outcomes, while radiation therapy (adjusted OR 0.10, <em>p</em> = 0.033) was protective.</p></div><div><h3>Conclusions</h3><p>GTR significantly improved PFS in treating PCNSLs, particularly in solitary cases. For patients with dominant tumors measuring ≥ 3 cm, cytoreductive surgery may improve OS. Neither cytoreductive surgery nor GTR correlated with poor functional outcomes.</p></div>","PeriodicalId":10385,"journal":{"name":"Clinical Neurology and Neurosurgery","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurology and Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0303846724004384","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

The role of tumor resection remains undetermined in treating primary central nervous system lymphomas (PCNSLs). This study aimed to clarify the impact of tumor resection on survival and functional outcomes, and to identify subgroups benefiting from resection.

Methods

We retrospectively reviewed records from 2010 to 2021 for PCNSL diagnosed at Chang Gung Memorial Hospital, Linkou. Patients were categorized by extent of resection: gross total resection (GTR), partial resection (PR), and biopsy. Univariate and multivariate analyses were performed to identify prognostic factors for survival and functional outcomes. Subgroup analysis was conducted to characterize patients who benefit from tumor resection.

Results

Of 88 patients, 12 had GTR, 25 had PR, and 51 received biopsy. GTR correlated with longer progression free survival (PFS) (HR 0.25, p=0.039), remaining significant in multivariate analysis (adjusted HR 0.09, p=0.004). In solitary PCNSLs, GTR also independently predicted longer PFS (adjusted HR 0.13, p= 0.023). Patients with dominant tumors measuring ≥ 3 cm trended towards improved overall survival (OS) with cytoreductive surgery versus biopsy (median survival 38.6 months vs 22.3 months, p=0.083). Age ≥ 60 years (adjusted OR 16.9, p = 0.008) and preoperative Karnofsky Performance Scale ≤ 70 (adjusted OR 4.97, p = 0.049) predicted poorer functional outcomes, while radiation therapy (adjusted OR 0.10, p = 0.033) was protective.

Conclusions

GTR significantly improved PFS in treating PCNSLs, particularly in solitary cases. For patients with dominant tumors measuring ≥ 3 cm, cytoreductive surgery may improve OS. Neither cytoreductive surgery nor GTR correlated with poor functional outcomes.

目的肿瘤切除在治疗原发性中枢神经系统淋巴瘤(PCNSL)中的作用仍未确定。本研究旨在阐明肿瘤切除对生存和功能预后的影响,并确定从切除中获益的亚组。方法我们回顾性审查了林口长庚纪念医院在2010年至2021年期间诊断的PCNSL病历。患者按切除范围分类:全切除(GTR)、部分切除(PR)和活检。进行了单变量和多变量分析,以确定生存和功能结果的预后因素。结果 88例患者中,12例接受了GTR,25例接受了PR,51例接受了活检。GTR与较长的无进展生存期(PFS)相关(HR 0.25,P=0.039),在多变量分析中仍有意义(调整后HR 0.09,P=0.004)。在单发 PCNSL 中,GTR 也能独立预测较长的 PFS(调整 HR 0.13,p= 0.023)。显性肿瘤≥3厘米的患者接受细胞切除手术与活检相比,总生存期(OS)有改善趋势(中位生存期38.6个月 vs 22.3个月,P=0.083)。年龄≥60岁(调整后OR值为16.9,P=0.008)和术前Karnofsky表现量表≤70(调整后OR值为4.97,P=0.049)预示着较差的功能预后,而放疗(调整后OR值为0.10,P=0.033)则具有保护作用。对于显性肿瘤≥3厘米的患者,细胞剥脱手术可改善OS。囊肿剥除手术和GTR均与不良功能预后无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Neurology and Neurosurgery
Clinical Neurology and Neurosurgery 医学-临床神经学
CiteScore
3.70
自引率
5.30%
发文量
358
审稿时长
46 days
期刊介绍: Clinical Neurology and Neurosurgery is devoted to publishing papers and reports on the clinical aspects of neurology and neurosurgery. It is an international forum for papers of high scientific standard that are of interest to Neurologists and Neurosurgeons world-wide.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信